Review Article
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Table 4
Anti-EGFR mAbs monotherapy or in combination with chemotherapy for therapy naïve mCRC selected by KRAS.
| Trial (author) |
Phase |
KRAS |
Protocol |
Number enrolled | Results |
HR (95% CI) | value | PFS | OS |
| Crystal (Van Cutsem et al.) [20] | III | WT | FOLFIRI + cetuximab FOLFIRI | 172 176 | 9.9 mos. 8.7 mos. | 24.9 mos. 21.0 mos. | PFS: 0.68 (0.50–0.94) OS: 0.84 (0.64–1.11) | 0.07 NR | MUT | FOLFIRI + cetuximab FOLFIRI | 105 87 | 7.6 mos. 8.1 mos. | 17.5 mos. 17.7 mos. | PFS: 1.07 (0.71–1.61) OS: 1.03 (0.74–1.44) | 0.44 NR |
| OPUS (Bokemeyer et al.) [21] | II | WT | FOLFOX + cetuximab FOLFOX | 61 73 | 7.7 mos. 7.2 mos. | | PFS: 0.57 (0.35–0.90) | 0.0163 | MUT | FOLFOX + cetuximab FOLFOX | 52 47 | 5.5 mos. 8.6 mos. | | PFS: 1.83 (1.09–3.05) | 0.192 |
| PRIME (Douillard et al.) [22] | III | WT | FOLFOX + panitumumab FOLFOX | 325 331 | 9.6 mos. 8.0 mos. | 23.9 mos. 19.7 mos. | PFS: 0.80 (0.66–0.97) OS: 0.83 (0.67–1.01) | 0.02 0.072 | MUT | FOLFOX + panitumumab FOLFOX | 221 219 | 7.3 mos. 8.8 mos. | 15.5 mos. 19.3 mos. | PFS: 1.29 (1.04–1.62) OS: 1.24 (0.98–1.57) | 0.02 0.68 |
|
|
WT: wild type, MUT: mutated, PFS: progression free survival, OS: overall survival, and NR: not reported.
|